BACKGROUND: The optimal treatment for locally advanced superior sulcus tumors is not clear. The authors report long-term results of a trial examining the safety and efficacy of surgery followed by concurrent chemoradiation therapy for this disease. METHODS: Thirty-two patients with resectable or marginally resectable superior sulcus tumors at The University of Texas MD Anderson Cancer Center from 1994 to 2010 were enrolled in a prospective trial. Surgery involved segmentectomy or lobectomy with en bloc resection of the involved chest wall and complete nodal staging; radiation therapy (RT) began 14 to 42 days later to a dose of 60 grays (Gy) in 50 1.2-Gy fractions if surgical margins were negative or 64.8 Gy in 54 1.2-Gy fractions if margins were positive. Two cycles of etoposide (50 mg/m(2) ) and cisplatin (50 mg/m(2) ) were given during RT, and another 3 cycles were given after RT. Eleven patients underwent prophylactic cranial irradiation (PCI). RESULTS: The protocol completion rate was 78%. Gross total resection was accomplished in all 32 patients; 28% underwent R1 resection. Operative mortality was 0%. The most common surgical complication was postoperative pneumonia (25%). At a median follow-up time of 53.4 months (range, 2-154 months), the 2-year, 5-year, and 10-year rates of locoregional control were 84%, 76%, and 76%; distant metastasis-free survival, 52%, 48%, and 48%; disease-free survival, 49%, 45%, and 45%; and overall survival, 72%, 50%, and 45%, respectively. The brain was the most common site of distant failure (n = 5), but no patient who received PCI experienced brain metastasis. CONCLUSIONS: Surgery followed by postoperative chemoradiation is safe and effective for the treatment of marginally resectable superior sulcus tumors.
BACKGROUND: The optimal treatment for locally advanced superior sulcus tumors is not clear. The authors report long-term results of a trial examining the safety and efficacy of surgery followed by concurrent chemoradiation therapy for this disease. METHODS: Thirty-two patients with resectable or marginally resectable superior sulcus tumors at The University of Texas MD Anderson Cancer Center from 1994 to 2010 were enrolled in a prospective trial. Surgery involved segmentectomy or lobectomy with en bloc resection of the involved chest wall and complete nodal staging; radiation therapy (RT) began 14 to 42 days later to a dose of 60 grays (Gy) in 50 1.2-Gy fractions if surgical margins were negative or 64.8 Gy in 54 1.2-Gy fractions if margins were positive. Two cycles of etoposide (50 mg/m(2) ) and cisplatin (50 mg/m(2) ) were given during RT, and another 3 cycles were given after RT. Eleven patients underwent prophylactic cranial irradiation (PCI). RESULTS: The protocol completion rate was 78%. Gross total resection was accomplished in all 32 patients; 28% underwent R1 resection. Operative mortality was 0%. The most common surgical complication was postoperative pneumonia (25%). At a median follow-up time of 53.4 months (range, 2-154 months), the 2-year, 5-year, and 10-year rates of locoregional control were 84%, 76%, and 76%; distant metastasis-free survival, 52%, 48%, and 48%; disease-free survival, 49%, 45%, and 45%; and overall survival, 72%, 50%, and 45%, respectively. The brain was the most common site of distant failure (n = 5), but no patient who received PCI experienced brain metastasis. CONCLUSIONS: Surgery followed by postoperative chemoradiation is safe and effective for the treatment of marginally resectable superior sulcus tumors.
Authors: V W Rusch; K R Parekh; L Leon; E Venkatraman; M S Bains; R J Downey; P Boland; M Bilsky; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 2000-06 Impact factor: 5.209
Authors: V W Rusch; D J Giroux; M J Kraut; J Crowley; M Hazuka; D Johnson; M Goldberg; F Detterbeck; F Shepherd; R Burkes; T Winton; C Deschamps; R Livingston; D Gandara Journal: J Thorac Cardiovasc Surg Date: 2001-03 Impact factor: 5.209
Authors: M Suntharalingam; J R Sonett; M L Haas; L A Doyle; P F Hausner; J Schuetz; M J Krasna Journal: Cancer J Date: 2000 Nov-Dec Impact factor: 3.360
Authors: Elizabeth M Gore; Kyounghwa Bae; Stuart J Wong; Alexander Sun; James A Bonner; Steven E Schild; Laurie E Gaspar; Jeffery A Bogart; Maria Werner-Wasik; Hak Choy Journal: J Clin Oncol Date: 2010-12-06 Impact factor: 44.544
Authors: T Umsawasdi; M Valdivieso; T T Chen; H T Barkley; D J Booser; D F Chiuten; H M Dhingra; W K Murphy; C L Dixon; P Farha Journal: J Neurooncol Date: 1984 Impact factor: 4.130
Authors: A H Russell; T E Pajak; H M Selim; J C Paradelo; K Murray; P Bansal; J D Cooper; S Silverman; J A Clement Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: Kemp H Kernstine; James Moon; Michael J Kraut; Katherine M W Pisters; Joshua R Sonett; Valerie W Rusch; Charles R Thomas; Thomas K Waddell; James R Jett; Alan P Lyss; Steven M Keller; David R Gandara Journal: Ann Thorac Surg Date: 2014-06-28 Impact factor: 4.330